Search Results

Beta-lactams and Beta-lactamase-inhibitors in current- or potential-clinical practice: A comprehensive update

Authors: Shahid, M.; Sobia, F.; Singh, A.; Malik, A.; Khan, H. M.; Jonas, D.; Hawkey, P. M.

Source: Critical Reviews in Microbiology, Volume 35, Number 2, May 2009 , pp. 81-108(28)

Publisher: Informa Healthcare

What's new and not so new on the antimicrobial horizon?

Author: French, G. L.

Source: Clinical Microbiology & Infection, Volume 14, Supplement 6, December 2008 , pp. 19-29(11)

Publisher: Blackwell Publishing

Population Pharmacokinetics of Meropenem in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy

Authors: Isla, Arantxazu; Rodríguez-Gascón, Alicia; Trocóniz, Iñaki F.; Bueno, Lorea; Solinís, María Ángeles; Maynar, Javier; Sánchez-Izquierdo, José Ángel; Pedraz, José Luis

Source: Clinical Pharmacokinetics, Volume 47, Number 3, 2008 , pp. 173-180(8)

Publisher: Adis International

Parenteral carbapenems

Author: Shah, P. M.

Source: Clinical Microbiology & Infection, Volume 14, Supplement 1, January 2008 , pp. 175-180(6)

Publisher: Blackwell Publishing

Vancomycin-resistant Enterococcus faecium infection in patients with hematologic malignancy: patients with acute myeloid leukemia are at high-risk

Authors: Worth, Leon J.; Thursky, Karin A.; Seymour, John F.; Slavin, Monica A.

Source: European Journal of Haematology, Volume 79, Number 3, September 2007 , pp. 226-233(8)

Publisher: Blackwell Publishing

Anti-MRSA β-lactams in development, with a focus on ceftobiprole: the first anti-MRSA β-lactam to demonstrate clinical efficacy

Authors: Bush, Karen; Heep, Markus; Macielag, Mark J; Noel, Gary J

Source: Expert Opinion on Investigational Drugs, Volume 16, Number 4, April 2007 , pp. 419-429(11)

Publisher: Informa Healthcare

Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice

Authors: Burkhardt, Olaf; Derendorf, Hartmut; Welte, Tobias

Source: Expert Opinion on Pharmacotherapy, Volume 8, Number 2, February 2007 , pp. 237-256(20)

Publisher: Informa Healthcare

Two decades of imipenem therapy

Authors: Rodloff, A. C.; Goldstein, E. J. C.; Torres, A.

Source: Journal of Antimicrobial Chemotherapy, Volume 58, Number 5, November 2006 , pp. 916-929(14)

Publisher: Oxford University Press

Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections

Authors: Saballs, Mireia; Pujol, Miquel; Tubau, Fe; Peña, Carmen; Montero, Abelardo; Domínguez, M. Angeles; Gudiol, Francesc; Ariza, Javier

Source: Journal of Antimicrobial Chemotherapy, Volume 58, Number 3, September 2006 , pp. 697-700(4)

Publisher: Oxford University Press

Nursing Home-Acquired Pneumonia: Update on Treatment Options

Author: Mylotte, Joseph M.

Source: Drugs & Aging, Volume 23, Number 5, 2006 , pp. 377-390(14)

Publisher: Adis International

Impact of diversity of antibiotic use on the development of antimicrobial resistance

Authors: Sandiumenge, Alberto; Diaz, Emili; Rodriguez, Alejandro; Vidaur, Loreto; Canadell, Laura; Olona, Montserrat; Rue, Montserrat; Rello, Jordi

Source: Journal of Antimicrobial Chemotherapy, Volume 57, Number 6, June 2006 , pp. 1197-1204(8)

Publisher: Oxford University Press

OXA β-lactamases in Acinetobacter: the story so far

Authors: Brown, Susan; Amyes, Sebastian

Source: Journal of Antimicrobial Chemotherapy, Volume 57, Number 1, January 2006 , pp. 1-3(3)

Publisher: Oxford University Press

Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003)

Authors: Fritsche, T. R.; Stilwell, M. G.; Jones, R. N.

Source: Clinical Microbiology & Infection, Volume 11, Number 12, December 2005 , pp. 974-984(11)

Publisher: Blackwell Publishing

Doripenem: S 4661

Author: Limited A.I.

Source: Drugs in R&D, Volume 4, Number 6, 2003 , pp. 363-365(3)

Publisher: Adis International

Application of cross-coupling reactions in Merck

Author: Yasuda N.

Source: Journal of Organometallic Chemistry, Volume 653, Number 1, 1 July 2002 , pp. 279-287(9)

Publisher: Elsevier

Identification by LC/MSⁿ of degradates of a novel carbapenem antibiotic in an aqueous matrix

Authors: Zhao Z.; Qin X.-Z.; Reed R.A.

Source: Journal of Pharmaceutical and Biomedical Analysis, Volume 29, Number 1, 20 June 2002 , pp. 173-181(9)

Publisher: Elsevier

Evaluation of the in vitro activity of six broad-spectrum -lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories

Authors: The India Antimicrobial Resistance Study Group; Mathai D.; Rhomberg P.R.; Biedenbach D.J.; Jones R.N.

Source: Diagnostic Microbiology and Infectious Disease, Volume 44, Number 4, December 2002 , pp. 367-377(11)

Publisher: Elsevier

Chromosomally-Encoded Resistance Mechanisms of Pseudomonas aeruginosa: Therapeutic Implications

Author: Lister P.D.

Source: American Journal of PharmacoGenomics, Volume 2, Number 4, 2002 , pp. 235-243(9)

Publisher: Adis International

Biapenem

Authors: Perry C.M.; Ibbotson T.

Source: Drugs, Volume 62, Number 15, 2002 , pp. 2221-2234(14)

Publisher: Adis International

Current Status of Oral Carbapenem Development

Authors: Kumagai T.; Tamai S.; Abe T.; Hikda M.

Source: Current Medicinal Chemistry - Anti-Infective Agents, Volume 1, Number 1, January 2002 , pp. 1-14(13)

Publisher: Bentham Science Publishers